Notizie e Video - COHORT ORD 10P - Pagina 2

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort PR Newswire SAN DIEGO and CALGARY, AB, Dec. 3, 2024 Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without atezolizumab The study will begin with 30 patients, with an option to expand to an additional 34 participants SAN DIEGO and CALGARY, AB , Dec. 3, 2024 /PRNewswire/...

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that the first patient has been dosed – as part of the expansion cohort – in Japan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The dosing of the first...

Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial PR Newswire SAN JOSE, Calif., Nov. 18, 2024 Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose SAN JOSE, Calif. , Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the third cohort in...

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) PR Newswire WALTHAM, Mass., Nov. 13, 2024 High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a biomarker indicative of epithelial health and lung function decline, suggesting potential therapeutic effect...

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR Newswire VICTORIA, BC, Nov. 12, 2024 One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI 1 ) scores at 12 weeks. At 24 weeks, the fourth cohort...

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy PR Newswire SAN DIEGO, Oct. 30, 2024 Biomarker cohort for delpacibart braxlosiran (del-brax), the first potential therapy to target DUX4, is measuring changes in DUX4 regulated biomarkers; del-brax 2 mg/kg will be administered every six weeks Enrollment in the del-brax...

Grantees Celebrated at First-Ever One House Filmmakers Fund Soiree at Academy Museum of Motion Pictures on October 26, 2024 LOS ANGELES, CA / ACCESSWIRE / October 28, 2024 / The nonprofits Sundance Institute and Gold House are thrilled to announce the second cohort of the Sundance Institute | One House Filmmakers Fund , providing unrestricted financing, educational support, and amplification for filmmakers from historically underrepresented communities. The fund is made possible by the generous...

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction PR Newswire SUMMIT, N.J. and BOSTON, Oct. 24, 2024 Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has...

Demonstrating the Utility of Blood Biomarkers in Predicting Amyloid Beta Accumulation in the Brain TOKYO, Oct 17, 2024 - (JCN Newswire) - Shimadzu Corporation, Eisai Co., Ltd., Oita University, and Usuki City Medical Association have demonstrated the utility of blood biomarkers in predicting the accumulation of amyloid beta (Abeta)(1) in the brain, a noted cause of Alzheimer's disease(2), in a cohort study conducted in Usuki City, Oita from November 2022. A research paper reporting the details...

PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration PR Newswire DAEJEON, South Korea, Oct. 14, 2024 Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascending dose 4 mg cohort. PMC-403 is being explored in broader therapeutic areas, including rare vascular disease systemic capillary leak syndrome (SCLS) and kidney diseases....

Open to Faculty and Academic Staff from Higher Education Institutions in the U.S. and Puerto Rico GRAND RAPIDS, MI / ACCESSWIRE / October 14, 2024 / Teach Access , a national nonprofit that bridges the digital accessibility skills gap-a gap in accessibility knowledge and digital skills among students graduating and entering the workforce-is excited to announce the opening of applications for its Fellowship Program 2025 cohort. This program brings together educators and administrators dedicated...

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) PR Newswire AUSTIN, Texas, Sept. 23, 2024 Cohort 2 will evaluate high-dose LTI-03 (5 mg BID) Previously announced Cohort 1 data demonstrated positive trends in seven of the eight biomarkers evaluated, suggesting a potential therapeutic effect AUSTIN, Texas , Sept. 23, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a...

By prioritizing freedom of inquiry, civil discourse, and intellectual pluralism, new university aims to renew the ideals of American higher education AUSTIN, TX / ACCESSWIRE / September 9, 2024 / Today, the University of Austin (UATX) begins its first academic year, welcoming its inaugural freshman class of 92 students. These students are the first to experience UATX's transformative approach to the college experience, grounded in open inquiry, liberal education, and a commitment to intellectual...

Lowe's Foundation Skilled Trades Workforce Investment Eclipses $25 Million Through New Cohort of Community and Technical College Gable Grants Recipients PR Newswire MOORESVILLE, N.C., July 23, 2024 From Arizona to Maine , 11 schools receive support to scale training and remove education barriers for sought-after trades careers MOORESVILLE, N.C. , July 23, 2024 /PRNewswire/ -- The Lowe's Foundation today announced nearly $8 million in Gable Grants to a second cohort of community and technical...

NORTHAMPTON, MA / ACCESSWIRE / July 17, 2024 / Ray C. Anderson Foundation: Meet 2024's Top 10 Nature-Inspired Startups Working to Solve Crucial Environmental and Social Problems The Biomimicry Institute , a not-for-profit organization focused on realizing a nature-positive, inclusive and regenerative world inspired and guided by nature's genius, today announced the 10 startups selected to participate in the transformational Ray of Hope Accelerator . The six-month accelerator is designed to...

PharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors PR Newswire DAEJEON, South Korea, July 8, 2024 PMC-309 receives safety approval for first dose cohort (0.2mg/kg), and second dose cohort (0.5mg/kg) is currently underway in Australia . DAEJEON, South Korea , July 8, 2024 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on next-generation antibody...

Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics PR Newswire HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 HONG KONG and GERMANTOWN, Md. and SUZHOU, China , July 8, 2024 /PRNewswire/ -- Sirnaomics Ltd . (the " Company ", together with its subsidiaries, the " Group " or " Sirnaomics "; stock code: 2257), a leading biopharmaceutical company engaging...

Cicada Innovations calls for systems approach to 'turbocharge' Future Made in Australia act, announces Tecdiv3 cohort PR Newswire SYDNEY, July 2, 2024 SYDNEY , July 2, 2024 /PRNewswire/ -- Australia's flagship deep tech incubator Cicada Innovations is urging the tech ecosystem to lead in turbocharging the Future Made in Australia act by shifting from a "silos" to a "systems" approach that aligns national vision with implementation. The call comes as Cicada announces the 23 ventures chosen to...

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients PR Newswire ROCKVILLE, Md., June 24, 2024 Company to begin enrollment of patients aged 1-3 years Expects data from younger cohort to be part of pivotal plans and BLA filing for broad label End-of-Phase II meeting with FDA scheduled for late July to finalize pivotal program design Based on recent commercial landscape, confirmed accelerated approval pathway remains available given ongoing unmet...

BOSTON, MA / ACCESSWIRE / June 18, 2024 / MassRobotics , in collaboration with Festo , Mitsubishi Electric Automation , Novanta , and MITRE , announces the opening of applications for the fourth cohort of the Healthcare Robotics Startup Catalyst Program 2024-25. This initiative aims to accelerate innovation and adoption in the healthcare robotics sector by providing startups with the resources, mentorship, and connections necessary for success. Apply here . Program Overview The Healthcare...